Stimulation of fibroblast proliferation by neokyotorphin requires Ca 2+ influx and activation of PKA, CaMK II and MAPK/ERK

FEBS Journal

Volumn 274, Issue 2, 2007, Pages 474-484

  Sazonova, Olga V ^a   Blishchenko, Elena Yu ^a   Tolmazova, Anna G ^a   Khachin, Dmitry P ^a   Leontiev, Konstantin V ^a   Karelin, Andrey A ^a   Ivanov, Vadim T ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Hemoglobin fragment; Intracellular Ca2+ protein kinase; Proliferation; Tissue homeostasis

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BISINDOLYLMALEIMIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NEOKYOTORPHIN; NIFEDIPINE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN; PROTEIN KINASE (CALCIUM,CALMODULIN) II; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; ANTICONVULSANTS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CHELATING AGENTS; ENDORPHINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FLAVONOIDS; ISOQUINOLINES; MAP KINASE SIGNALING SYSTEM; MICE; NIFEDIPINE; PROTEIN KINASE INHIBITORS; SULFONAMIDES; VERAPAMIL;

EID: 33846024684     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2006.05594.x     Document Type: Article

References (55)

1. Takagi H, Shiomi H, Fucui K, Hayashi K, Kiso Y & Kitagava K (1982) Isolation of a novel peptide, neokyotorphin from bovine brain. Life Sci 31, 1733-1736.
2. Hazato T, Kase R, Takagi H & Katayama T (1986) Inhibitory effects of the analgesic neuropeptides kyotorphin and neokyotorphin on enkephalin-degrading enzymes from monkey brain. Biochem Int 12, 379-383.
3. Ueda H, Ge M, Satoh M & Takagi H (1987) Non-opioid analgesia of the neuropeptide neokyotorphin and possible mediation by inhibition of GABA release in the mouse brain. Peptides 8, 905-909.
4. Ivanov V, Blishchenko E, Sazonova O & Karelin A (2003) What to synthesize? From Emil Fischer to peptidomics. J Peptide Sci 9, 553-562.
5. Blishchenko E, Mernenko O, Yatskin O, Ziganshin R, Phillipova M, Karelin A & Ivanov V (1996) Neokyotorpin and neokyotorpin(1-4): cytolitic activity and comparative levels in rat tissues. Biochem Biophys Res Commun 224, 721-727.
6. Blishchenko E, Mernenko O, Yatskin O, Ziganshin R, Phillipova M, Karelin A & Ivanov V (1997) Neokyotorpin and neokyotorpin(1-4): secretion by erythrocytes and regulation of tumor cell growth. FEBS Lett 414, 125-128.
7. Bronnikov G, Dolgacheva L, Zhang S, Galitocskaya E, Kramarova L & Zinchenko V (1997) The effect of neuropeptides kyotorphin and neokyotorphin on proliferation of cultured brown preadipocytes. FEBS Lett 407, 73-77.
8. Blishchenko E, Kalinina O, Sazonova O, Khaidukov S, Egorova N, Surovoy A, Philippova M, Vass A, Karelin A & Ivanov V (2001) Endogenous fragment of hemoglobin, neokyotorphin, as cell growth factor. Peptides 22, 1999-2008.
9. Sazonova O, Blishchenko E, Kalinina O, Egorova N, Surovoy A, Philippova M, Karelin A & Ivanov V (2003) Proliferative activity of neokyotorphin-related hemoglobin fragments in cell cultures. Protein Peptide Lett 10, 386-395.
10. Scarpa R, Carraway R & Cochrane D (2004) The effect of neurotensin on insulin-induced proliferation of human fibroblasts. Peptides 25, 1159-1169.
11. Ganz M, Perfetto M & Boron W (1990) Effects of mitogens and other agents on rat mesangial cell proliferation, pH, and Ca2+. Am J Physiol 259, 269-278.
12. Kokoz Y, Zenchenko K, Alekseev A, Ziganshin R, Mikhaleva I & Ivanov V (1997) The effect of some peptides from the hibernating brain on Ca2+ current in cardiac cells and on the activity of septal neurons. FEBS Lett 411, 71-76.
13. Dolmetsch R, Pajvani U, Fife K, Spotts J & Greenberg M (2001) Signalling to the nucleus be an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science 294, 333-339.
14. Wang X, Nagaba Y, Cross H, Wrba F, Zhang L & Guggino S (2000) The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. Am J Pathol 157, 1549-1562.
15. Lijnen P & Petrov V (1999) Proliferation of human peripheral blood mononuclear cells during calcium entry blockade. Role of protein kinase C. Methods Find Exp Clin Pharmacol 21, 253-259.
16. Agafonova I, Aminin D, Shubina L & Fedorov S (2002) Influence of polyhydroxysteroids on [Ca(2+)](i). Steroids 67, 695-701.
17. Larsson-Backstrom C, Arrhenius E & Sagge K (1985) Comparison of the calcium-antagonistic effects of terodiline, nifedipine and verapamil. Acta Pharmacol Toxicol 57, 8-17.
18. Tamaoki T (1991) Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. Methods Enzymol 201, 340-347.
19. Ruegg U (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 10, 218-220.
20. Ko J, Park W & Earm Y (2005) The protein kinase inhibitor, staurosporine, inhibits 1-type Ca2+ current in rabbit atrial myocytes. Biochem Biophys Res Commun 329, 531-537.
21. Braun M & Mochly-Rosen D (2003) Opposing effects of delta- and zeta-protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors. J Mol Cell Cardiol 35, 895-903.
22. Stork P & Schmitt J (2002) Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12, 258-266.
23. Withers D, Coppock H, Seufferlein T, Smith D, Bloom S & Rozengurt E (1996) Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. FEBS Lett 378, 83-87.
24. Leicht M, Greipel N & Zimmer H (2000) Comitogenic effect of catecholamines on rat cardiac fibroblast culture. Cardiovasc Res 48, 274-284.
25. McKenzie F & Pouyssegur J (1996) cAMP-mediated growth inhibition in fibroblasts is not mediated via mitogen-activated (MAP) kinase (ERK) inhibition. cAMP-dependent protein kinase induces a temporal shift in growth factor-stimulated MAP kinases. J Biol Chem 271, 13476-13483.
26. Pearson G & Cobb M (2002) Cell condition-dependent regulation of ERK5 by cAMP. J Biol Chem 277, 48094-48098.
27. Young S, Dickens M & Tavare J (1994) Differentiation of PC12 cells in response to cAMP analogue is accompanied by sustained activation of mitogen-activated protein kinase. FEBS Lett 338, 212-216.
28. Kvanta A & Fredholm B (1993) Synergistic effects between protein kinase C and cAMP on activator protein-1 activity and differentiation of PC-12 pheochromocytoma cells. J Mol Neurosci 4, 205-214.
29. Davies S, Reddy H, Caivano M & Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95-105.
30. Cass L, Summers S, Prendergast G, Backer J, Birnbaum M & Meinkoth J (1999) Protein kinase A-dependent and -independent signaling pathways contribute to cyclic AMP-stimulated proliferation. Mol Cell Biol 19, 5882-5891.
31. Drobic B, Espino P & Davie J (2004) Mitogen- and stress-activated protein kinase 1 activity and histone h3 phosphorylation in oncogene-transformed mouse fibroblasts. Cancer Res 64, 9076-9079.
32. Wiggin G, Soloaga A, Foster J, Murray-Tait V, Cohen P & Arthur J (2002) MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22, 2871-2881.
33. Goode N & Hart I (1990) Protein kinase C levels and protein phosphorylation associated with inhibition of proliferation in a murine macrophage tumor. J Cell Physiol 142, 480-487.
34. Davis P, Elliott L, Harris W, Hill C, Hurst S, Keech E, Kumar M, Lawton G, Nixon J & Wilkinson S (1992) Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J Med Chem 35, 994-1001.
35. Birchall A, Bishop J, Bradshaw D, Cline A, Coffey J, Elliott L, Gibson V, Greenham A, Hallam T, Harris W et al. (1994) Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation. J Pharmac Exp Ther 268, 922-929.
36. Acs P, Wang Q, Bögi K, Marquez A, Lorenzo P, Bíro T, Szállási Z, Mushinski J & Blumberg P (1997) Both the catalytic and regulatory domains of protein kinase C chimeras modulate the proliferative properties of NIH 3T3 cells. J Biol Chem 272, 28793-28799.
37. Soderling T, Chang B & Brickey D (2001) Cellular signaling through multifunctional Ca2+/calmodulin-dependent protein kinase II. J Biol Chem 276, 3719-3722.
38. Kamp T & Hell J (2000) Regulation of cardiac 1-type calcium channels by protein kinase A and protein kinase C. Circ Res 8, 1095-1102.
39. Gomez E, Pritchard C & Herbert T (2002) cAMP-dependent protein kinase and Ca2+ influx through 1-type voltage-gated calcium channel mediate Raf-independent activation of extracellular regulated kinase in response to glucagons-like peptide-1 in pancreatic β-cells. J Biol Chem 277, 48146-48151.
40. Ferguson G & Storm D (2004) Why calcium-stimulated adenylyl cyclases? Physiology (Bethesda) 19, 271-276.
41. Grewal S, Horgan A, York R, Withers G, Banker G & Stork P (2000) Neuronal calcium activates a Rap1 and B-Raf signaling pathway via the cyclic adenosine monophosphate-dependent protein-kinase. J Biol Chem 275, 3722-3728.
42. Dumaz N & Marais R (2005) Integrating signals between cAMP and the RAS/RAF/MEK/ERK signaling pathways. FEBS J 272, 3491-3504.
43. Pritchard C, Hayes L, Wojnowski L, Zimmer A, Marais R & & Rman J (2004) B-Raf Acts via the ROCKII/LIMK/Cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol 24, 5937-5952.
44. Wojnowski L, Stancato L, Larner A, Rapp U & Zimmer A (2000) Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev 91, 97-104.
45. Kamata T, Kang J, Lee T-H, Wojnowski L, Pritchard C & Leavitt A (2005) A critical function for B-Raf at multiple stages of myelopoiesis. Blood 106, 833-840.
46. Vossler M, Yao H, Pan M, Rim C & Stork P (1997) cAMP activates MAP kinase and Elk-1 through a B-Raf and Rap-1-dependent pathway. Cell 89, 73-82.
47. Qui W, Zhuang S, von Lintig F, Boss G & Pilz R (2000) Cell type-specific regulation of B-Raf kinase by cAMP and 14-3-3 proteins. J Biol Chem 275, 31921-31929.
48. Pardo O, Wellbrock C, Khanzada U, Aubert M, Arozarena I, Davidson S, Bowen F, Parker P, Filonenko V, Gout I et al. (2006) FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 25, 3078-3088.
49. Ikenoue T, Hikiba Y, Kanai F, Aragaki J, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K et al. (2004) Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res 64, 3428-3435.
50. Erhardt P, Schremser E & Cooper G (1999) B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19, 5308-5315.
51. Rubin H (2005) Degrees and kinds of selection in spontaneous transformation: an operational analysis. Proc Natl Acad Sci USA 102, 9276-9281.
52. Ito E, Sonnenberg J & Narayanan R (1989) Nerve growth factor-induced differentiation in PC-12 cells is blocked by fos oncogene. Oncogene 4, 1193-1199.
53. Takahashi H, Honma M, Miyauchi Y, Nakamura S, Ishida-Yamamoto A & Iizuka H (2004) Cyclic AMP differently regulates cell proliferation of normal human keratinocytes through Erk activation depending on the expression pattern of B-Raf. Arch Dermatol Res 296, 74-82.
54. Ivanov V, Yatskin O, Sazonova O, Tolmazova A, Leontiev K, Filippova M, Karelin A & Blishchenko E (2006) Peptidomics: a modern approach to biodiversity of peptides. Pure Appl Chem 78, 963-975.
55. Fruitier I, Garreau I, Lacroix A, Cupo A & Piot J (1999) Proteolytic degradation of hemoglobin by endogenous lysosomal proteases gives rise to bioactive peptides: hemorphins. FEBS Lett 447, 81-86.